Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Kyverna Therapeutics, Inc. Common Stock

Kyverna Therapeutics is a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna’s pipeline includes KYV-101, a fully human, autologous chimeric antigen receptor (CAR) T-cell therapy with properties well suited for use in B cell-driven autoimmune diseases and KYV-201, a fully human, allogeneic CAR T-cell therapy.  

By offering more than one mechanism for taming autoimmunity, and with patients currently in treatment for multiple indications in the U.S. and Europe, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated.

Vida Ventures

Westlake Village BioPartners

The Argentum Group

CAM Capital

LYFE Capital

RTW Investments

Gilead Sciences

Hudson Bay Capital Management

Insight Partners

Intellia Therapeutics

Bain Capital Life Sciences

Northpond Ventures

GordonMD Global Investments

Kyverna Therapeutics

Ingenui-T uses whole blood from a standard draw, providing a less-invasive alternative to apheresis and offering an improved vein-to-vein experience to patients in need. Our CEO Peter Maag, PhD, and CTO Karen Walker share more about our CAR T #celltherapy, the recent FDA's fast-track clearance of KYV-101 to treat multiple sclerosis, and the priority to establish relationships with CAR T centers with Genetic Engineering & Biotechnology News's Jonathan D. Grinstein, PhD.

#celltherapy #autoimmunediseases

https://lnkd.in/evCJaKDD

Dr. Borie, President, R&D and Dr. Chung, CMO shared the stage with several industry veterans in Silicon Valley this week to discuss the advancements in CAR T-cell therapy and our commitment to patient care. Thank you PMWC - Precision Medicine World Conference for the opportunity to spread the excitement!

#cartcelltherapy #autoimmunediseases #trailblazers

https://www.pmwcintl.com

Ingenui-T is our novel, proprietary method to manufacture chimeric antigen receptor (CAR) T cells from a single whole blood draw, thereby improving patient experience, and their caregivers. Read more about it in the BioRxiv article published today:

https://lnkd.in/eudXgcMx

Apheresis presents challenges with its lengthy and invasive procedure. The high demand for apheresis beds, limited capacity, and resource constraints at collection centers further complicate the process. Kyverna's method addresses these challenges, marking a significant advancement in streamlining the patient experience.

 #cartcelltherapy #autoimmunedisease

https://lnkd.in/eV_XeJWm

As CAR T-cell therapies expanded into the autoimmune space, it was great to be able to present Phacilitate in Miami, FL last week our innovative approaches to change the treatment paradigm.

#cartcelltherapy #autoimmunediseases #Advancedtherapies

 https://lnkd.in/evk77ci7

Kyverna is developing #cartcelltherapy that aims to reset the immune system and provide new hope to individuals suffering from autoimmune conditions, with a focus on #rheumatology and #neurology, by leveraging a patient-centric approach.

Speaking with Xtalks, CEO Peter Maag shares Kyverna's focus on #autoimmunedisease and a vision for the future of autoimmune treatment that could make a tangible difference in patients’ lives.

https://lnkd.in/eXHi5FjB

Our investigational #cartcelltherapy, KYV-101, has received fast track designation from #FDA for use in #multiplesclerosis patients. This marks a significant step forward in our mission to change the paradigm in #autoimmunedisease treatment.

https://lnkd.in/e5hPcJtJ

Our President of R&D, Dominic Borie, M.D., Ph.D., and our CMO, James Chung, are speaking at the #PMWC24 2024 Precision Medicine World Conference in Santa Clara this January 24 and will share more insights on how Kyverna is committed to developing #cartcelltherapy for patients living with #autoimmunedisease. With multiple patients treated for multiple indications at various sites across the world, we believe in shifting the treatment paradigm for serious rheumatological and neuro-immunological autoimmune conditions. 

https://lnkd.in/eb9jkcuz

We're excited to have James Chung, CMO, and Tom Van Blarcom, Senior Vice President and Head of Research, represent Kyverna Therapeutics at Phacilitate.

Join us as James discusses "KYV-101: a Fully Human Autologous CAR T-Cell Therapy for Autoimmune Diseases", and Tom presents on "Kyverna Therapeutics: Transformative Outcomes With Autologous CAR T-Cell Therapy for Autoimmune Diseases.”  

Learn more at https://lnkd.in/evk77ci7

#celltherapy #autoimmunediseases

Our Investigational New Drug application for KYV-101 has received FDA clearance for patients with treatment-refractory progressive #multiplesclerosis, enabling a new therapeutic option that can potentially result in sustained treatment-free remission and alleviate risks of long-term toxicities.

#celltherapy #cart #biopharma

https://lnkd.in/e7UbvFia

Our warmest wishes of the Season to everyone dedicated to changing the paradigm in the treatment of autoimmune diseases.
#cartcelltherapy #autoimmunedisease

	Dec '21	Dec '22	Dec '23
account payables	773K -	1.45M 87.71%	4.36M 200.34%
accumulated other comprehensive income loss		-26K -	4K 115.38%
cash and cash equivalents	76.07M -	37.73M 50.39%	34.65M 8.18%
cash and short term investments	76.07M -	51.32M 32.53%	57.54M 12.12%
common stock
deferred revenue	6M -	7.66M 27.68%	9.06M 18.29%
deferred revenue non current	1.02M -
deferrred tax liabilities non current	109.97M -
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt	4.74M -	8.29M 74.79%	6.16M 25.68%
long term investments	552K -	554K 0.36%	565K 1.99%
net debt	-70.51M -	-27.17M 61.47%	-25.57M 5.90%
net receivables
other assets
other current assets	1.02M -	1.93M 89.12%	3.12M 61.79%
other current liabilities	8.34M -	565K 93.23%	3.52M 522.83%
other liabilities
other non current assets	41K -	678K 1,553.66%	3.36M 394.99%
other non current liabilities	78K -	120.68M 154,617.95%	180.57M 49.63%
othertotal stockholders equity	-108.19M -	-118.97M 9.96%	-175.93M 47.88%
preferred stock	108.72M -	120.67M 11.00%	180.57M 49.64%
property plant equipment net	7.81M -	12.44M 59.34%	10.61M 14.72%
retained earnings	-46.78M -	-75.68M 61.76%	-136.04M 79.77%
short term debt	814K -	2.28M 179.73%	2.92M 28.24%
short term investments		13.59M -	22.90M 68.51%
tax assets
tax payables
total assets	85.49M -	66.92M 21.72%	75.19M 12.36%
total current assets	77.09M -	53.25M 30.92%	60.66M 13.92%
total current liabilities	15.93M -	11.95M 24.95%	19.86M 66.13%
total debt	5.55M -	10.56M 90.17%	9.08M 14.06%
total investments	552K -	13.59M 2,361.41%	22.90M 68.51%
total liabilities	131.74M -	140.92M 6.97%	206.59M 46.60%
total liabilities and stockholders equity	85.49M -	66.92M 21.72%	75.19M 12.36%
total non current assets	8.40M -	13.67M 62.75%	14.53M 6.28%
total non current liabilities	115.81M -	128.97M 11.36%	186.73M 44.79%
total stockholders equity	-46.25M -	-74.00M 59.98%	-131.40M 77.57%

KYTX

COM:KYVERNATX

Kyverna TX

Last Close

3.99

22/11 21:00

Market Cap

364.75M

Beta: -

Volume Today

269.18K

Avg: -

Preview